BRPI0508596A - combinação compreendendo ligante alfa-2-delta - Google Patents
combinação compreendendo ligante alfa-2-deltaInfo
- Publication number
- BRPI0508596A BRPI0508596A BRPI0508596-9A BRPI0508596A BRPI0508596A BR PI0508596 A BRPI0508596 A BR PI0508596A BR PI0508596 A BRPI0508596 A BR PI0508596A BR PI0508596 A BRPI0508596 A BR PI0508596A
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- alpha
- delta ligand
- delta
- specifically
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 2
- 208000002193 Pain Diseases 0.000 abstract 1
- 239000003693 atypical antipsychotic agent Substances 0.000 abstract 1
- 229940127236 atypical antipsychotics Drugs 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMBINAçãO COMPREENDENDO LIGANTE ALFA-2-DELTA. A presente invenção refere-se à combinação, especificamente uma combinação sinérgica de um ligante alfa-2-delta e um antipsicótico atípico e sais farmaceuticamente aceitáveis dos mesmos, composições farmacêuticas dos mesmos e seu uso no tratamento da dor, especificamente dor neuropática.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0405200.7A GB0405200D0 (en) | 2004-03-08 | 2004-03-08 | Combinations comprising alpha-2-delta ligands |
US56041604P | 2004-04-07 | 2004-04-07 | |
PCT/IB2005/000510 WO2005092318A1 (en) | 2004-03-08 | 2005-02-24 | Combinations comprising alpha-2-delta ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0508596A true BRPI0508596A (pt) | 2007-08-21 |
Family
ID=32117256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0508596-9A BRPI0508596A (pt) | 2004-03-08 | 2005-02-24 | combinação compreendendo ligante alfa-2-delta |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070191350A1 (pt) |
EP (1) | EP1727535A1 (pt) |
JP (1) | JP2007527905A (pt) |
BR (1) | BRPI0508596A (pt) |
CA (1) | CA2559266A1 (pt) |
GB (1) | GB0405200D0 (pt) |
WO (1) | WO2005092318A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69722426T3 (de) | 1996-07-24 | 2015-05-07 | Warner-Lambert Company LLC (n.Ges. des Staates Delaware) | Isobutylgaba und dessen derivate zur schmerzbehandlung |
WO2009136375A1 (en) * | 2008-05-08 | 2009-11-12 | Pfizer Inc | Treatment of interstitial cystitis |
KR101810246B1 (ko) | 2008-10-08 | 2017-12-18 | 엑스진 파마슈티컬 인크. | Gaba 접합체 및 그의 사용 방법 |
US20110269727A1 (en) * | 2010-04-29 | 2011-11-03 | Toledano Annette C | Composition to reduce allodynic back pain and related method of use |
US9205081B2 (en) | 2010-04-29 | 2015-12-08 | Allodynic Therapeutics, Llc | Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain |
US9095548B2 (en) | 2010-04-29 | 2015-08-04 | Allodynic Therapeutics, Llc | Combinations of opioid/TLR4 antagonists and acetyl-para-aminophenol (APAP) for use in the treatment of pain |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US20180147201A1 (en) | 2016-10-31 | 2018-05-31 | Allodynic Therapeutics, Llc | Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia |
CA3047451A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
JP7149287B2 (ja) | 2016-12-20 | 2022-10-06 | エルテーエス ローマン テラピー-ジステーメ アーゲー | アセナピンおよびポリシロキサンまたはポリイソブチレンを含有する経皮治療システム |
EP3644973B1 (en) | 2017-06-26 | 2021-03-24 | LTS LOHMANN Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6361957B1 (en) * | 1999-08-03 | 2002-03-26 | Glytech, Inc. | Assay for D-serine transport antagonist and use for treating psychosis |
US6372792B1 (en) * | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
US6611706B2 (en) * | 1998-11-09 | 2003-08-26 | Transpharma Ltd. | Monopolar and bipolar current application for transdermal drug delivery and analyte extraction |
TWI312285B (en) * | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
AU2003248907B2 (en) * | 2002-07-11 | 2007-04-26 | Merck & Co., Inc. | Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds |
GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
CN1791430A (zh) * | 2003-05-16 | 2006-06-21 | 辉瑞产品公司 | 非典型抗精神病药物和gaba调节剂、抗惊厥药物或苯并二氮杂䓬类的治疗性组合 |
MXPA06005019A (es) * | 2003-11-03 | 2006-07-06 | Warner Lambert Co | Nuevos inhibidores de la recaptacion de norpinefrina para el tratamiento de transtornos del sistema nervioso central. |
-
2004
- 2004-03-08 GB GBGB0405200.7A patent/GB0405200D0/en not_active Ceased
-
2005
- 2005-02-24 WO PCT/IB2005/000510 patent/WO2005092318A1/en active Application Filing
- 2005-02-24 US US10/598,712 patent/US20070191350A1/en not_active Abandoned
- 2005-02-24 EP EP05708623A patent/EP1727535A1/en not_active Withdrawn
- 2005-02-24 JP JP2007502427A patent/JP2007527905A/ja not_active Withdrawn
- 2005-02-24 BR BRPI0508596-9A patent/BRPI0508596A/pt not_active IP Right Cessation
- 2005-02-24 CA CA002559266A patent/CA2559266A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2559266A1 (en) | 2005-10-06 |
EP1727535A1 (en) | 2006-12-06 |
GB0405200D0 (en) | 2004-04-21 |
US20070191350A1 (en) | 2007-08-16 |
WO2005092318A1 (en) | 2005-10-06 |
JP2007527905A (ja) | 2007-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0508596A (pt) | combinação compreendendo ligante alfa-2-delta | |
BRPI0509993A (pt) | combinações compreendendo ligandos de alfa-2-delta | |
EA200802166A1 (ru) | Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью | |
BRPI0916877A2 (pt) | composição farmacêutica e administração da mesma | |
RS51569B (en) | COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL | |
UA94734C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ | |
BRPI0615157A2 (pt) | composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto | |
EA200801997A1 (ru) | Новые соединения | |
ATE510538T1 (de) | Zusammensetzungen und verfahren für nervenschutz | |
EA201200550A1 (ru) | Фармацевтические композиции, включающие bi-1356 и метформин | |
IL195030A (en) | IV dpp inhibitor assemblies | |
ATE456369T1 (de) | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen | |
GT200900057A (es) | 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato | |
MX2009014235A (es) | 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso. | |
BRPI0607198A2 (pt) | composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica | |
EA200970532A1 (ru) | Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола | |
EA201170512A1 (ru) | Композиция для перорального введения | |
AR054595A1 (es) | Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis | |
ATE494889T1 (de) | Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol | |
EP1896005A4 (en) | SYNERGISTIC PHARMACEUTICAL PREPARATIONS FOR USE IN THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF BETA-AMYLOID PROTEIN-INDUCED DISEASE, INCLUDING COMPOUNDS DERIVED FROM SAGE AND ROSEMARY | |
UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
EA200702282A1 (ru) | Комбинация феррохина и производного артемизинина для лечения малярии | |
CL2007002875A1 (es) | Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales. | |
WO2008042480A3 (en) | Epoxide inhibitors of cysteine proteases | |
BRPI0212298B8 (pt) | composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011. |